title: Allopurinol pretreatment improves postoperative recovery and reduces lipid peroxidation in patients undergoing coronary artery bypass grafting.
abstract: In this prospective, randomized, double-blind, placebo-controlled study, the clinical, biochemical, and hemodynamic effects of xanthine oxidase inhibition in patients undergoing coronary artery bypass grafting were assessed. Allopurinol pretreatment significantly reduced the use of inotropic support after the operation (5 of 25 patients versus 13 of 25 patients, p < 0.01) and increased the rate of peripheral warming (11.4 +/- 0.85 hours versus 14.4 +/- 1 hours, p < 0.02). Twenty patients (9 in the allopurinol group and 11 in the placebo group) underwent invasive hemodynamic monitoring and intraoperative coronary sinus cannulation. The cardiac indexes of both groups were similar before the operation and for the first postoperative hour; thereafter, the cardiac index increased significantly in only the active treatment group (F = 3.33 and df = 5.90, p < 0.004). Products of lipid peroxidation (thiobarbituric acid reactive substances) increased significantly in only the placebo group, with increases being evident both in the systemic circulation (9.5 +/- 3.2 nmol/gm albumin, p < 0.007, and 24 +/- 5 nmol/gm albumin, p < 0.001, at 30 seconds and 2 minutes of reperfusion, respectively) and the coronary sinus (19.4 +/- 5.8 nmol/gm albumin, p < 0.004, and 28 +/- 4 nmol/gm albumin, p < 0.001, at 2 and 5 minutes of reperfusion, respectively. No significant difference was evident between the groups with respect to cardiac enzyme or vitamin E release. It is proposed that xanthine oxidase inhibition exerts its beneficial effects by reducing the level of free radical activity associated with reperfusion during coronary artery bypass grafting.
authors.affiliation: Department of Cardiology, Harefield Hospital, Middlesex, England.
authors.forename: J G
authors.initials: JG
authors.lastname: Coghlan
authors.forename: W D
authors.initials: WD
authors.lastname: Flitter
authors.forename: S M
authors.initials: SM
authors.lastname: Clutton
authors.forename: R
authors.initials: R
authors.lastname: Panda
authors.forename: R
authors.initials: R
authors.lastname: Daly
authors.forename: G
authors.initials: G
authors.lastname: Wright
authors.forename: C D
authors.initials: CD
authors.lastname: Ilsley
authors.forename: T F
authors.initials: TF
authors.lastname: Slater
mesh_terms: D000328:Adult; D000368:Aged; D000493:Allopurinol / Q000627:therapeutic use*; D001026:Coronary Artery Bypass; D004311:Double-Blind Method; D005260:Female; D006324:Heart Arrest, Induced; D006439:Hemodynamics; D006801:Humans; D015227:Lipid Peroxidation / Q000187:drug effects*; D008297:Male; D008875:Middle Aged; D015428:Myocardial Reperfusion Injury / Q000517:prevention & control; D009206:Myocardium / Q000201:enzymology; D009599:Nitroprusside / Q000008:administration & dosage; D011182:Postoperative Care; D011300:Preoperative Care; D011446:Prospective Studies; D017392:Thiobarbituric Acid Reactive Substances; D014810:Vitamin E / Q000378:metabolism; D014969:Xanthine Oxidase / Q000037:antagonists & inhibitors
chemical_list: D017392:Thiobarbituric Acid Reactive Substances; D014810:Vitamin E; D009599:Nitroprusside; D000493:Allopurinol; D014969:Xanthine Oxidase